Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.39 |
| ▸ | MAPT | P10636 | 8/20 | 0.39 |
| ▸ | MEN1 | O00255 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3945589 | 1.00 | KDM4E (0.40) | KDM4EKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL3948474 | 0.91 | KDM4E (0.41) | KDM4EKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL3948472 | 0.91 | KDM4E (0.41) | KDM4EKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL3941735 | 0.90 | ALDH1A1 (0.51) | KDM4EKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL3941738 | 0.90 | ALDH1A1 (0.51) | KDM4EKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL3953772 | 0.89 | ALDH1A1 (0.38) | KDM4EKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL3953372 | 0.89 | ALDH1A1 (0.38) | KDM4EKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL3949479 | 0.85 | ALDH1A1 (0.40) | KDM4EKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL3949474 | 0.85 | ALDH1A1 (0.40) | KDM4EKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL3947795 | 0.85 | POLB (0.38) | KDM4EKMT2AMAPTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553845-B2 | Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives | SANOFI-AVENTIS (FR) | 2009-06-30 | — | — | US | disclosed |
| US-20060199962-A1 | Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives | SANOFI-AVENTIS (FR) | 2006-09-07 | — | — | US | disclosed |
| EP-1664047-A1 | SUBSTITUTED INDOLIZINE 1,2,3,6,7,8 DERIVATIVES, FGFS INHIBITORS, A METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | Sanofi-Aventis (FR) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005028476-A1 | SUBSTITUTED INDOLIZINE 1,2,3,6,7,8 DERIVATIVES, FGFS INHIBITORS, A METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | SANOFI-AVENTIS (FR) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199962-A1 | Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives | FGF1, FGF2, FGFR1 | KDM4E 1804/4885KMT2A 2957/4885MAPT 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.